Current eligibility focuses on patients with Type 2 diabetes and a high BMI, or those with significant cardiovascular risks
10.7717/peerj.18227 35 ShangguanM.ZhengJ.LiuN.ZhaoJ.WangQ
In T2D group, linagliptin significantly reduced HbA1c from baseline in both the low GLP-1 and high GLP-1 groups
The most frequently reported adverse effects are gastrointestinal and typically occur during treatment initiation or dose escalation: Nausea (very common): Usually mild to moderate and diminishing over time Diarrhoea (very common): Potentially contributing to dehydration Vomiting (common): Particularly during early treatment phases Constipation (common): Due to delayed gastric emptying Abdominal pain and dyspepsia (common): May affect eating and drinking patterns Decreased appetite (very common): A therapeutic effect that may inadvertently reduce fluid intake Other notable side effects include: Injection site reactions (erythema, pruritus, swelling) Fatigue and dizziness, which may be exacerbated by dehydration Hypoglycaemia, particularly when used with insulin or sulfonylureas (doses of these medications may need to be reduced when starting tirzepatide) Increased heart rate (modest elevation of 2-4 beats per minute) Gallbladder problems including gallstones and inflammation Potential worsening of diabetic retinopathy in patients with pre-existing disease According to NICE guidance , patients should be counselled about these expected side effects before initiating treatment
doi: 10.1177/1535370217733426
By week four, many patients find their new appetite set point feels normal, making calorie restriction sustainable rather than restrictive
.png.jpg)
